Europe Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product, By Clinical Indication, and End User

The Europe immunodiagnostics market is expected to grow from US$ 6,131.85 million in 2023 to US$ 10,098.03 million by 2030. It is estimated to grow at a CAGR of 7.4% from 2023 to 2030.

Increasing Prevalence of Infectious Diseases Drive Europe Immunodiagnostics Market

The diagnosis and management of several ever-growing infectious diseases caused by infectious agents such as viruses, fungi, bacteria, parasites, or their toxic products are surging number of prescriptions for immunodiagnostics tests, e.g., complement fixation, precipitation tests, agglutination tests, line blot assays, Western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests. Human immunodeficiency virus (HIV) continues to be a major public health issue worldwide. Further, tuberculosis (TB), COVID-19, and other hospital-acquired infections (HAIs) require immunodiagnostics tests.

• TB has been the 13th leading cause of death and the second-leading infectious killer after COVID-19. In 2020, 1.5 million people died from TB and affected an estimated 10 million people, comprising 5.6 million males, 3.3 million females, and 1.1 million children globally.

• According to Worldometer, millions of deaths were reported worldwide due to the COVID-19 pandemic. It strained healthcare systems and increased the need for immunodiagnostics tests.

Diagnostics play a vital role in determining suitable medical treatments. Immunodiagnostics help diagnose diseases that severely impact the immune system. Hence, the rising prevalence of infectious diseases lead to the surging demand for immunodiagnostics products.

Europe Immunodiagnostics Market Overview
The huge geriatric population is significantly driving the market for immunodiagnostics in Germany. According to the UN population data, 1 out of 20 Germans is aged above 80 years, and the number is expected to increase to 6 out of 20 by 2050. The risk of developing chronic diseases, such as cardiovascular diseases (CVDs), diabetes, and neurovascular disorders, increases with age. According to the estimates of the German Centre for Cancer Registry Data (ZfKD) published by the Robert Koch Institute in September 2023, in Germany, 502,655 people had cancer in 2019, among which 234,925 were women and 267,730 were men. It is estimated that the prevalence of cancer is likely to continue owing to lifestyle changes, obesity, unhealthy habits, and more. The most common cancers in Germany are breast, prostate, colorectum (large bowel), lung, and bladder cancer. These five cancer types accounted for about 57% of all new cancer diagnoses in Germany. Thus, the increasing prevalence of cancer is likely to propel the demand for immunodiagnostics.

Germany is the leading medical biotech nation in the world after the US. In 2020, the German biotechnology sector grew significantly compared to the pre-COVID year 2018. The positive market trend has accelerated in the last few years in some areas; and according to the OECD-compliant survey by BIOCOM, the German biotechnology industry’s turnover increased by almost 50% in 2020. The presence of long-established companies and the emergence of start-ups affirmed the industrial strength. Industry, government, and research sectors thrive on strong market foundations. With many European biotech companies, world-class research infrastructure, and internationally renowned scientists, Germany has firmly established itself as an international medical biotechnology hub. German biotech companies emerged as global leaders in mRNA technologies by introducing the first COVID-19 test and vaccination, approved by the European Medicines Agency. Such developments have encouraged enhanced technological advancements for immunodiagnostics. Thus, the rising biotechnology sector will likely boost the country's immunodiagnostics market.

Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

Europe Immunodiagnostics Market Segmentation

The Europe immunodiagnostics market is segmented into product, clinical indication, end user, and country.

Based on product, the Europe immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered the largest share in the Europe immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Europe immunodiagnostics market is segmented into infectious diseases, hepatitis+hiv, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered the largest share in the Europe immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Europe immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered the largest share in the Europe immunodiagnostics market.

Based on country, the Europe immunodiagnostics market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. In 2023, Germany segment registered the largest share in the Europe immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the Europe immunodiagnostics market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe immunodiagnostics market
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Europe immunodiagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the immunodiagnostics market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution